Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80 - Nature Cancer

  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Study reveals why immunotherapies don't work on hardest-to-treat breast cancers naturecancer

Boxes show three individual areas that have been and expanded, with indicated channels separated. Arrowheads mark p21 + /CD80 + and IRF1 + /PD-L1+ cells ; γH2AX + /CD80+ cells and γH2AX/PD-L1 negative cells ; p-Stat3+/PD-L1+ and p-Stat3 + /CD80+ cells .Untreated tumor stained and imaged in parallel. Scale bar=40 µm. qPCR and IF were repeated at least twice and representative data are shown.

CRISPR-Cas9 was used to generate a p53 knockout clone and a non-edited control of 4226 cell line.p53 knockout clone 2 of the 4226 cell line was untreated or treated with doxorubicin as indicated. Over 1 to 5 days, these cultures were then exposed to rIFNγ for 24 h ) or not , followed by immunoblot for CD80, PD-L1, Stat1, and IRF1 on a total of 2 membranes, which were then blotted for actin.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 101. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves AI-powered breast cancer screening toolBreast cancer screening AI app OK'd by watchdog
Source: TheRegister - 🏆 67. / 61 Read more »

Ovarian cancer mutational processes drive site-specific immune evasion - NatureMulti-modal analysis of genomically unstable ovarian tumours characterizes the contribution of anatomical sites and mutational processes to evolutionary phenotypic divergence and immune resistance mechanisms.
Source: medical_xpress - 🏆 101. / 51 Read more »

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A - Nature CommunicationsPhosphoproteomics is a promising tool for identifying biomarkers of treatment response in cancer. Here, the authors analyse proteomics profiling of HER2-negative female breast cancer patients and identify potential predictors of paclitaxel response. physorg_com NatureComms Now if they could just mitigate the destruction of the ovaries.
Source: medical_xpress - 🏆 101. / 51 Read more »